-+ 0.00%
-+ 0.00%
-+ 0.00%

Microchip Biotech (688321.SH): Clinical trial application for siglitazide sodium metformin extended-release tablets accepted

Zhitongcaijing·01/05/2026 12:41:03
Listen to the news

Zhitong Finance App News, Microchip Biotech (688321.SH) announced that the company and its wholly-owned subsidiary, Chengdu Microchip Pharmaceutical Co., Ltd., recently received a “Notice of Acceptance” issued by the Drug Evaluation Center of the State Drug Administration for the registration of domestically produced drugs. The clinical trial application for siglita sodium metformin sustained-release tablets independently developed by the company to treat adult patients with type 2 diabetes was accepted.

Siglitat sodium metformin sustained-release tablets are fixed-dose combination sustained-release formulations of siglitat sodium and metformin independently developed by the company. They treat type 2 diabetes through different mechanisms of action, so that patients can obtain better blood sugar control.